Circulate Health Publishes Results of Multiomics Study Demonstrating Impact of Therapeutic Plasma Exchange on Biological Age in Aging Cell

First-of-its kind trial shows that therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as measured by multi-omics biomarkers

NOVATO, Calif., May 28, 2025 /PRNewswire/ -- Circulate Health, the company dedicated to harnessing the potential of therapeutic plasma exchange (TPE) to advance human healthspan and lifespan, today announces the publication of a single blind, human clinical trial in Aging Cell.  This groundbreaking study, led by researchers from Circulate and the Buck Institute for Research on Aging provides promising early data on the impact of TPE on biological age, supporting its potential for new disease and longevity applications.

"Unfortunately, most so-called 'longevity interventions' lack proven effectiveness in humans. By conducting clinical trials, we aim to change that—this study marks the first step in demonstrating that plasma exchange can significantly improve key mechanisms of biological aging," commented Dr. David Furman, senior author of the Aging Cell paper.

Therapeutic plasma exchange is a procedure that separates, removes, and replaces patient plasma to treat certain diseases. Multi-omics Analysis Reveals Biomarkers that Contribute to Biological Age Rejuvenation in Response to Therapeutic Plasma Exchange, investigated how TPE impacts biomarkers associated with biological age, including changes across the epigenome, proteome, metabolome, glycome, and immune system, alongside physical measures like balance and strength.  Research participants were assigned one of four different treatment groups: 1) biweekly TPE, 2) biweekly TPE with intravenous immunoglobulin (IVIG) 3) monthly TPE or 4) a control group.

The study found:

• Patients receiving TPE showed a reduction in biological age, as measured by multi-omics biomarkers, with the most significant reductions in those patients that received TPE with IVIG. Participants undergoing biweekly TPE-IVIG treatment exhibited an average biological age reduction of 2.61 years, compared to 1.32 years for those receiving TPE alone.
• Patients receiving TPE with IVIG experienced changes in immune cells associated with reversed age-related immune decline. This intervention modulated cellular senescence-associated proteins and restored age-associated shifts in immune cell composition. This indicates that TPE with IVIG may improve the body's ability to fight infections and other age-related diseases, particularly those related to inflammation.
• Individuals with biomarkers associated with poorer baseline health status, including higher baseline levels of circulating bilirubin, glucose, and liver enzymes, saw the greatest reduction in biological age and improvement in biomarkers. The treatment also showed a benefit for healthy individuals, including in balance and strength.
• While the observed treatment effects were strongest after the initial three sessions, subsequent treatments showed diminishing returns, suggesting that spacing out treatments or combining them with other interventions may enhance long-term benefits.

"This is the first interventional multi-omics study to examine the effectiveness of therapeutic plasma exchange modalities," said Brad Younggren, MD, CEO and Co-founder of Circulate. "Our findings show that plasma exchange and intravenous immunoglobulin are a powerful tool for biological age rejuvenation and provide compelling evidence that targeted plasma interventions can impact age-related molecular changes."

"In this study, we examined thousands of molecular signatures to pinpoint key drivers of rejuvenation. Our characterization builds a better understanding of which baseline biomarkers are predictive of treatment response and lays a foundation upon which we can build personalized intervention plans for patients in the future," said Eric Verdin, MD, President and CEO of the Buck Institute and Co-founder of Circulate. "We are excited to expand our research to larger populations, increase access to these treatments for eligible patients, and continue to identify areas of unmet need where these therapies can make a meaningful difference."

Clinicians can learn more about Circulate at www.circulate.health.

About Circulate Health
Backed by Khosla Ventures, Circulate Health is pioneering technologies to reverse aging and improve health outcomes.

About Buck Institute 
Our success will ultimately change healthcare. At the Buck, we aim to end the threat of age-related diseases for this and future generations by bringing together the most capable and passionate scientists from a broad range of disciplines to identify and impede the ways in which we age. An independent, nonprofit institution, our goal is to increase human healthspan, or the healthy years of life. Globally recognized as the pioneer and leader in efforts to target aging, the number one risk factor serious diseases including Alzheimer's, Parkinson's, cancer, macular degeneration, heart disease, and diabetes, the Buck wants to help people live better longer.  Learn more at: https://buckinstitute.org

SOURCE Circulate Health